Oncology

Frontline amivantamab (Ryebrevant) plus lazertinib (Lazcluze) demonstrated a clinically meaningful and statistically significant survival improvement...

At the 2025 World Conference on Genitourinary Cancers (World GU), Oncology Decoded hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, spoke w...

Oncology Decoded hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, traveled to the 2025 World Conference on Genitourinary Cancers (World GU)...

During the Society of Hematological Oncology (SOHO) 2025 Annual Meeting, Lorenzo Falchi, MD, an oncologist and hematologist specializing in lymphoma a...

The addition of surufatinib (Sulanda) to durvalumab (Imfinzi), etoposide, and platinum-based chemotherapy displayed promising efficacy and a manageabl...

As part of the IASLC 2025 World Conference on Lung Cancer (WCLC), experts from around the world convened in Barcelona, Spain, to exhibit updated findi...

Purpose External control arms (ECAs) are sometimes considered as an alternative to phase III trials, enabling comparisons without head-to-head trials....

At the Society of Hematological Oncology 2025 Annual Meeting, Prithviraj Bose, MD, delivered a presentation titled “Individualizing Treatment Selectio...

Ronco G, Confortini M, Maccallini V, Naldoni C, Segnan N, Sideri M, et al. Health Technology Assessment Report. Uso della citologia in fase liquida ne...

Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59:34...